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Abstract (250 words) 110 
Objectives: To assess the risk factors for the development of late-onset invasive pulmonary 111 
aspergillosis (IPA) after kidney transplantation (KT). 112 
Methods: We performed a multinational case-control study that retrospectively recruited 112 KT 113 
recipients diagnosed with IPA between 2000 and 2013. Controls were matched (1:1 ratio) by 114 
center and date of transplantation. Immunosuppression-related events (IREs) included the 115 
occurrence of non-ventilator-associated pneumonia, tuberculosis, cytomegalovirus disease 116 
and/or de novo malignancy. 117 
Results: We identified 61 cases of late (>180 days after transplantation) IPA from 24 118 
participating centers (accounting for 54.5% [61/112] of all cases included in the overall study). 119 
Most diagnoses (54.1% [33/61]) were established within the first 36 post-transplant months, 120 
although 5 cases occurred more than 10 years after transplantation. Overall mortality among 121 
cases was 47.5% (29/61). Compared to controls, cases were significantly older (P-value = 122 
0.010) and more likely to have pre-transplant chronic obstructive pulmonary disease (P-value = 123 
0.001) and a diagnosis of bloodstream infection (P-value = 0.016) and IRE (P-value <0.001) 124 
within the 6 months prior to the onset of late IPA. After multivariate adjustment, previous 125 
occurrence of IRE (odds ratio: 19.26; 95% confidence interval: 2.07 - 179.46; P-value = 0.009) 126 
was identified as an independent risk factor for late IPA. 127 
Conclusion: More than half of IPA cases after KT occur beyond the sixth month, with some of 128 
them presenting very late. Late IPA entails a poor prognosis. We identified some risk factors 129 
that could help the clinician to delimit the subgroup of KT recipients at the highest risk for late 130 
IPA. 131 
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Introduction 132 
Invasive pulmonary aspergillosis (IPA) constitutes one of the most feared complications 133 
occurring in patients undergoing solid organ transplantation (SOT) in terms of both patient and 134 
graft survival [1-3]. Apart from local susceptibility associated with specific surgical procedures 135 
(e.g., ulcerative aspergillus tracheobronchitis at the bronchial anastomosis site after lung 136 
transplantation) [4], it is conventionally assumed that the lifelong use of immunosuppression to 137 
avoid graft rejection confers the most relevant risk for this event [5]. 138 
The intensity of the immunosuppressive therapy is usually higher during the first 6 months 139 
following SOT, and therefore this period has been traditionally considered as carrying the 140 
maximum risk for opportunistic infection including IPA [6]. Nevertheless, kidney transplant (KT) 141 
recipients require potent triple-drug regimens —often containing steroids, calcineurin inhibitors 142 
and antiproliferative agents— for indefinite time periods [7]. Although the relative risk of post-143 
transplant IPA after KT is lower compared to other types of grafts [1,3,8], KT recipients suffer 144 
from the highest absolute disease burden due to the large number of procedures performed 145 
worldwide [9,10]. In addition, recent decades have witnessed a continuous improvement in 146 
long-term graft survival [11], thus increasing the population of aged KT recipients chronically 147 
exposed to a high degree of immunosuppression. 148 
By using a multicenter case-control design, we have recently analyzed the risk factors for the 149 
occurrence of early IPA (i.e., diagnosed within the first 180 days) after KT [12]. Only one 150 
previous study has analyzed the predisposing conditions for the late forms of infection, although 151 
its results were limited by its single-center nature and by the inclusion of only 26 cases of late 152 
IPA [13]. 153 
Transplant physicians may benefit from identifying, among the increasing population of long-154 
term KT recipients, that subgroup of patients at increased risk for late IPA in order to implement 155 
individualized follow-up and prevention strategies. Unfortunately, such an approach remains an 156 
unmet clinical need. To the best of our knowledge, this is the first study specifically aiming to 157 
ascertain the predisposing factors for the development of late IPA from a large representative 158 
population of KT recipients. 159 
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Materials and Methods 160 
Study design 161 
This is a sub-analysis of a multinational retrospective case-control study performed in 29 162 
hospitals from 10 European (Spain, Switzerland [6 centers included in the Swiss Transplant 163 
Cohort Study [14]], Belgium, Portugal, France and United Kingdom) and American institutions 164 
(United States, Brazil, Mexico and Argentina). Participating centers included cases of IPA 165 
diagnosed in KT recipients between January 1, 2000 and December 31, 2013 [12,15]. In the 166 
present a priori designed sub-analysis we focused on late episodes of IPA, defined as those 167 
diagnosed beyond the first 180 days after transplantation (“IPA cases”). The “control group” was 168 
selected (in an 1:1 ratio) among those patients that underwent transplantation at the same 169 
center within a 3-month period before or after the calendar date of the corresponding case but 170 
without the diagnosis of IPA throughout the post-transplant period. In addition, controls must 171 
have survived at least until the time of diagnosis of IPA in the index case. To take into account 172 
the effect of post-transplant events on the occurrence of late IPA, controls were assigned a 173 
“pseudo-date of diagnosis” to match their cases with the aim of ensuring comparable risk 174 
exposure periods in both groups. The criteria used to establish the date of IPA diagnosis is 175 
available as Supplementary Methods. This research adhered to the STROBE guidelines for 176 
observational studies. The study protocol was approved by the local Ethics Committee of the 177 
coordinating center and of other participating sites as required. 178 
Study definitions 179 
IPA was defined according to the revised criteria proposed in 2008 by the European 180 
Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative 181 
Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group 182 
(EORTC/MSG) Consensus Group (details provided as Supplementary Methods) [16]. It 183 
should be noted that we added a modified radiological criterion (beyond the classic dense, well-184 
circumscribed lesions with or without halo sign or cavitation) based on the presence of certain 185 
lung patterns that have been specifically associated with post-transplant IPA (peribronchial 186 
consolidation or tree-in-bud pattern) [17]. Additional study definitions (including IPA-attributable 187 
mortality, cytomegalovirus [CMV] disease, tuberculosis, pneumonia, respiratory tract viral 188 
infection, bloodstream infection [BSI] or post-transplant lymphoproliferative disorder [PTLD]) are 189 
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available in Supplementary Methods. 190 
To encompass the different post-transplant complications that may be attributable to over-191 
immunosuppression we constructed a composite variable (termed “immunosuppression-related 192 
event” [IRE]) that included the occurrence of any of the following: non-ventilator-associated 193 
pneumonia, tuberculosis, CMV disease and/or post-transplant de novo malignancy (both PTLD 194 
and solid organ tumors). Community-acquired pneumonia has been previously recognized to be 195 
more frequent among SOT recipients due to immunosuppression [18] and therefore 196 
pneumococcal vaccination is strongly recommended for this population [19]. We did not 197 
consider within the definition of IRE certain post-transplant infections (such as BSI or ventilator-198 
associated pneumonia) that may be arguably attributable to invasive procedures, 199 
instrumentation (i.e., indwelling catheters) or anatomical abnormalities rather than to the 200 
recipient’s immune status. 201 
Statistical analysis 202 
Continuous variables were summarized by the mean ± standard deviation (SD) or the median 203 
with interquartile ranges (IQR), while categorical variables were summarized using absolute 204 
counts and percentages. Categorical variables were compared using the McNemar test, 205 
whereas the Student's t-test for repeated measures or the Wilcoxon signed-ranks test were 206 
applied for continuous variables. Conditional logistic regression was used to identify 207 
independent risk factors for the development of late IPA. Those variables found to be significant 208 
(P-value ≤0.1) at the univariate level were included into the multivariable models in a backward 209 
stepwise fashion. Collinearity among explanatory variables was assessed by means of the 210 
variance inflation factor (VIF), with VIF values over 3 suggesting significant collinearity. Results 211 
are given as odds ratios (ORs) with 95% confidence intervals (CIs). As a secondary outcome, 212 
we compared patient survival from the date (for cases) or the “pseudodate” (for controls) of IPA 213 
diagnosis. Survival curves were plotted by the Kaplan-Meier method and differences between 214 
groups were compared with the log-rank test. All the significance tests were two-tailed. 215 
Statistical analysis was performed with SPSS version 20.0 (IBM Corp., Armonk, NY) and 216 
graphics were generated with Prism v. 6.0 (GraphPad Software Inc., La Jolla, CA). 217 
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Results 218 
We included 61 cases of late IPA (14/61 [23.0%] proven and 47/61 [77.0%] probable) and their 219 
corresponding controls from 24 out of 29 participating centers (i.e., 5 centers did not contribute 220 
to the present sub-analysis). This figure accounts for 54.5% (61/112) of all the cases enrolled in 221 
the overall study. Twenty-nine out of 61 cases (47.5%) were diagnosed between 2010 and 222 
2013. The median time interval between transplantation and diagnosis was 34.4 months (IQR: 223 
11.8 - 78.5). Most diagnoses (54.1% [33/61]) were established within the first 36 months, 224 
although this period spanned more than 27 years (with 5 very late-onset cases occurring after 225 
the tenth year) (Figure 1). The median follow-up from the date (for cases) or the “pseudo-date” 226 
of diagnosis (for controls) was 476 days (IQR: 70.0 - 1298.5). Overall and IPA-attributable 227 
mortality among IPA cases was 47.5% (29/61) and 21.3% (13/61) and occurred at a median of 228 
53.5 days (IQR: 14.5 - 171.5) and 15 days (IQR: 7.3 - 33.3), respectively, from diagnosis. There 229 
were no significant differences in one-year survival rates between cases occurring in months 6 230 
to 36 or >36 months after transplantation (55.0% versus 41.0%, respectively; log-rank test P-231 
value = 0.619). Among survivors, 9.4% (3/32) patients experienced definitive graft failure 232 
requiring return to permanent dialysis. None of the patients in the control group died during the 233 
follow-up. One-year survival was significantly lower among cases than controls (49.0% versus 234 
100.0%; log-rank test P-value = 0.021). 235 
The demographics and pre-transplant factors of patients who developed late IPA and their 236 
controls are compared in Table 1. Cases were significantly older (54.6 ± 14.2 versus 48.6 ± 237 
15.5 years; P-value = 0.010) and more likely to have pre-transplant chronic obstructive 238 
pulmonary disease (COPD) (18.0% [11/61] versus 0.0% [0/61]; P-value = 0.001) than control 239 
counterparts. The prevalence of underlying diabetic nephropathy as a reason for end-stage 240 
renal disease requiring transplantation was also higher among cases, although not achieving 241 
statistical significance (19.7% [12/61] versus 6.6% [4/61]; P-value = 0.077). 242 
Donor- and transplant-related and post-transplant variables are compared in Table 2. Cases 243 
were more likely to have been diagnosed with an IRE during the 6 months prior to the onset of 244 
IPA (34.4% [21/61] versus 3.3% [2/61]; P-value <0.001), with significant (for non-ventilator-245 
associated pneumonia and CMV disease) or near significant differences (for post-transplant de 246 
novo malignancy) observed for each of the different individual events included in this composite 247 
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variable. PTLD was the predominant type of malignancy diagnosed. A prior occurrence of BSI 248 
was also more common among cases than controls (11.5% [7/61] versus 0.0% [0/61]; P-value = 249 
0.016). No significant differences were observed between the groups regarding the prior 250 
occurrence of acute graft rejection or the requirement of steroid boluses. None of these 251 
episodes were treated with lymphocyte-depleting agents as anti-rejection therapy, and only one 252 
of them (in the control group) received rituximab. 253 
Finally, age at transplantation, pre-transplant COPD, underlying diabetic nephropathy, and the 254 
diagnosis of an IRE or BSI within the preceding 6 months were entered into the conditional 255 
logistic regression model (Table 3). Linear regression analysis showed no significant collinearity 256 
among these explanatory variables, with all VIF values <1.5 (data not shown). After multivariate 257 
adjustment, prior diagnosis of IRE (OR: 19.26; 95% CI: 2.07 - 179.46; P-value = 0.009) was 258 
identified as the only independent risk factor associated with late IPA. 259 
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Discussion 260 
To our knowledge, our multinational retrospective case-control study represents the largest 261 
effort to date to explore the clinical outcome of and risk factors for IPA in the specific population 262 
of KT recipients. Our experience highlights the poor prognosis conferred by the late forms of 263 
this opportunistic infection, since more than half of the included patients had died at a median 264 
time of less than two months from diagnosis. In addition, IPA-attributable mortality was 265 
assumed in more than 20% of cases. Notwithstanding such an ominous picture, in our previous 266 
study we reported even worse figures for early IPA (first 180 days), with global and attributable 267 
mortality of 60.8% and 45.1%, respectively [12]. We hypothesize that this difference may be 268 
explained by the relatively more intensive immunosuppression among patients in their first post-269 
transplant months [15]. 270 
Remarkably, although most of the episodes of late IPA occurred within the first three years, 271 
almost 10% of them were diagnosed across a large time period covering more than a decade 272 
after transplantation, including some very late onset episodes occurring more than ten years 273 
post-transplantation. In a previous series of IPA among KT recipients [13], 43% of the 41 cases 274 
were diagnosed beyond the sixth month, and 6 (14%) beyond the fifth year post-transplantation. 275 
These concordant results reinforce the previously stated concept [20] that the period at risk for 276 
severe opportunistic infection continues far beyond the classical time scheme proposed for SOT 277 
recipients. 278 
Despite the wide range of time between KT and the onset of late IPA, we were still able to 279 
identify some factors associated to this event. Cases were more likely to have been diagnosed 280 
with COPD, although such association only showed borderline univariate significance. The 281 
presence of pre-transplant COPD may reflect underlying injury to the lung parenchyma [12,21] 282 
or act as a surrogate marker for prolonged corticosteroid exposure. BSI during the six preceding 283 
months was also more frequent among cases. Comparable associations have been previously 284 
reported for the overall SOT population [8] or, specifically, KT recipients [12]. The occurrence of 285 
BSI may identify patients commonly suffering from invasive procedures, impaired graft function 286 
and antibiotic therapy exposure, which overall reflect increased patient frailty.  287 
Following the example of previous studies [22], we created a composite variable (IRE) that 288 
summarized post-transplant complications —such as severe non-device-associated infections, 289 
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CMV disease or de novo cancer— that are consistently assumed to indicate an excess of 290 
immunosuppression. In the regression model this condition displayed a significant association 291 
with the development of IPA during the following six months. Other authors have also reported 292 
the observation of episodes of pneumonia preceding the onset of IPA [23,24]. On the other 293 
hand, the deleterious impact exerted by CMV on the risk of IPA has been well established for 294 
the SOT recipient [8,25,26]. In accordance with this rationale, the incidence of CMV disease in 295 
our experience was ten times higher among cases than controls (16.4% versus 1.6%, 296 
respectively). In a similar way, a recent diagnosis of de novo cancer (either PTLD or solid organ 297 
tumor) had been made in almost one out of every ten cases as compared to none of the 298 
controls. In a French nationwide epidemiological study, both hematologic and solid organ 299 
malignancies have been described as an important risk factor for invasive aspergillosis [3]. In 300 
addition to the direct deleterious effect of the oncologic therapies (B-cell-depleting agents such 301 
as rituximab or cytotoxic chemotherapy) on the host’s response and infection susceptibility, the 302 
function of natural killer cells (which significantly contribute to the protective immunity against 303 
fungi [27]) has been shown to be impaired in KT recipients with post-transplant cancer [28]. 304 
The design of our study (case-control study) prevents us from estimating the actual incidence of 305 
late IPA among KT recipients that develop an episode of IRE. Case-control studies can 306 
generate plausible associations rather than demonstrate direct causality. In our opinion, such a 307 
circumstance and the heterogeneous distribution of IPA cases over a very long post-transplant 308 
period would make it unreasonable to propose the use of antifungal prophylaxis for those 309 
recipients fulfilling the characterized risk factors. Nevertheless, our findings do support the 310 
recommendation of maintaining a low threshold for suspicion of post-transplant IPA in patients 311 
with compatible respiratory symptoms and underlying COPD or recently diagnosed with a 312 
serious infection, CMV disease or post-transplant cancer. In addition, this clinical awareness 313 
should be maintained even for very long-term KT recipients, as IPA may occur many years after 314 
transplantation. In this context, we have previously shown the protean clinical features of IPA 315 
among KT recipients and the correlation between the timely initiation of antifungal therapy and 316 
the outcome [15].  317 
Strengths of the present collaborative effort include its multicenter nature, the use of uniform 318 
diagnostic criteria, and the standardized collection of a large number of variables. However, 319 
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some limitations must be acknowledged, such as its retrospective design and the relatively low 320 
sample size that may have limited statistical power. Therefore, confidence intervals for risk 321 
estimates were wide. Most IPA cases were categorized as “probable” rather than “proven” [16]. 322 
The protracted inclusion period imposes heterogeneity among participating centers in 323 
immunosuppression and standard of care. Nonetheless, the low incidence among KT recipients 324 
of late-onset IPA made this approach the only practical method to collect a meaningful number 325 
of cases. We lacked detailed data on certain relevant factors (such as the receipt of rituximab or 326 
cytotoxic chemotherapy among patients with PTLD). Finally, we were unable to estimate the 327 
incidence of late IPA due to the lack of denominator figures (i.e., number of transplant 328 
procedures performed at each center or number of at-risk recipients during the study period) 329 
since our research was conceived exclusively to ascertain the risk factors for developing such 330 
condition. Thus, we chose a case-control design instead than other approaches (i.e., nested 331 
case-control study within a multicenter cohort). 332 
In conclusion, late IPA may develop among KT recipients even more than 10 years after 333 
transplantation and entails a very poor prognosis. The preceding diagnosis of post-transplant 334 
adverse events reflecting an excess of immunosuppression, such as serious or opportunistic 335 
infection or de novo malignancy, may be useful to identify those patients at the highest risk for 336 
this complication. 337 
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Tables 467 
Table 1. Comparison of demographics and pre-transplant variables between KT recipients with 468 
and without late IPA. 469 
Variable Late IPA group (n = 61) 
Control group 
(n = 61) P-value
a 
Age, years [mean ± SD] 54.6 ± 14.2 48.6 ± 15.5 0.010 
Gender (male) [n (%)] 33 (54.1) 38 (62.3) 0.458 
Pre-transplant conditions [n (%)]    
Diabetes mellitus 18 (29.5) 9 (14.7) 0.093 
Chronic obstructive pulmonary disease 11 (18.0) 0 (0.0) 0.001 
Pre-transplant corticosteroid therapy [n (%)]b 6 (10.3) 5 (8.8) 0.754 
BMI at transplantation, Kg/m2 [mean ± SD]c 24.3 ± 3.6 26.7 ± 7.3 0.074 
Previous kidney transplantation [n (%)] 7 (11.5) 8 (13.1) 1.000 
Underlying end-stage renal disease [n (%)]    
Glomerulonephritis 14 (23.0) 14 (23.0) 1.000 
Diabetic nephropathy 12 (19.7) 4 (6.6) 0.077 
Nephroangiosclerosis 8 (13.1) 8 (13.1) 1.000 
Polycystic kidney disease 8 (13.1) 11 (18.0) 0.824 
Chronic interstitial nephropathy 3 (4.9) 3 (4.9) 1.000 
Congenital nephropathy 2 (3.3) 3 (4.9) 1.000 
Lupus nephropathy 1 (1.6) 1 (1.6) 1.000 
Reflux nephropathy 0 (0.0) 1 (1.6) 1.000 
Unknown 6 (9.8) 9 (14.8) 0.388 
Other 7 (11.5) 7 (11.5) 0.549 
Pre-transplant positive serostatus [n (%)]    
Hepatitis C virus 6 (9.8) 1 (1.6) 0.125 
Hepatitis B virus (surface antigen) 2 (3.3) 4 (6.6) 0.625 
Epstein-Barr virus (anti-EBNA)d 49 (87.5) 47 (83.9) 0.754 
CMVe 45 (73.8) 45 (75.0) 1.000 
Pre-transplant maintenance dialysis [n (%)] 55 (90.2) 54 (88.5) 1.000 
Duration, months [median (IQR)] 23 (15 - 41) 19.5 (12 - 45.8) 1.000 
CMV: cytomegalovirus; EBNA: Epstein-Barr virus nuclear antigen; HBc: hepatitis B core antigen; ICU: 
intensive care unit; IPA: invasive pulmonary aspergillosis; IQR: interquartile range; SD: standard deviation. 
a Significant P-values (<0.05) are expressed in bold. 
b Data available for 58 cases and 57 controls. 
c Data available for 43 cases and 43 controls. 
d Data available for 56 cases and 56 controls. 
e Data available for 61 cases and 60 controls. 
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Table 2. Comparison of donor- and transplant-related factors, post-transplant events and 470 
outcomes.  471 
Variable Late IPA group (n = 61) 
Control group 
(n = 61) P-value
a 
Age of donor, years [mean ± SD] 49.8 ± 16.3 46.8 ± 13.5 0.283 
Living donor [n (%)] 12 (19.7) 12 (19.7) 1.000 
Double kidney transplantation [n (%)] 3 (4.9) 0 (0.0) 0.250 
Induction therapy [n (%)]b    
None 22 (36.7) 20 (33.9) 1.000 
Anti-CD25 (basiliximab or daclizumab) 22 (36.7) 20 (33.9) 0.815 
Anti-thymocyte globulin 16 (26.7) 19 (32.2) 0.648 
Primary immunosuppression regimen including [n 
(%)]b 
   
Steroids 54 (88.5) 57 (93.4) 0.375 
Tacrolimus 29 (48.3) 30 (50.8) 1.000 
Cyclosporine 19 (31.7) 20 (33.9) 1.000 
MMF / MPA 47 (78.3) 50 (84.7) 0.375 
Azathioprine 5 (8.5) 7 (11.9) 0.375 
mTOR inhibitor 6 (10.0) 2 (3.4) 0.219 
Length of hospital admission for transplantation, 
days [median (IQR)] 
12 (8 - 18.8) 11 (6.3 - 18.8) 0.314 
Delayed graft function [n (%)] 13 (21.3) 8 (13.1) 0.388 
Surgical reintervention [n (%)]c 6 (10.2) 2 (3.7) 0.687 
eGFR at month 3 after transplantation, 
mL/min/1.72 m2 [mean ± SD]d 
23.8 ± 3.2 25.6 ± 3.4 0.873 
eGFR at month 6 after transplantation, 
mL/min/1.72 m2 [mean ± SD]e 
22.9 ± 3.1 20.5 ± 2.8 0.159 
Leukopenia (<3.0 x 109 cells/L) [n (%)]f,g 10 (16.9) 6 (10.2) 0.388 
Neutropenia (<1.5 x 109 cells/L) [n (%)]f,h 6 (12.2) 3 (6.2) 0.687 
Serum IgG levels, mg/dL [mean ± SD]i 879 ± 627 763 ± 571 0.750 
Post-transplant events within the previous 6 
months [n (%)]j 
   
IREk,l 21 (34.4) 2 (3.3) 0.000 
CMV disease 10 (16.4) 1 (1.6) 0.004 
Non ventilator-associated pneumonia 9 (14.8) 1 (1.6) 0.021 
De novo malignancym 5 (8.2) 0 (0.0) 0.063 
Laboratory-confirmed respiratory tract viral 
infectionn 
5 (8.2) 0 (0.0) 0.063 
Bloodstream infectiono 7 (11.5) 0 (0.0) 0.016 
ICU admission for ≥72 hours 2 (3.3) 0 (0.0) 0.500 
Acute graft rejection 4 (6.6) 5 (8.2) 1.000 
Episode treated with steroid boluses 4 (4.9) 5 (8.2) 0.687 
Overall mortality [n (%)] 29 (47.5) 0 (0.0) 0.001 
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IPA-attributable mortality [n (%)] 13 (21.3) - NA 
CMV: cytomegalovirus; eGFR: estimated glomerular filtration rate; ICU: intensive care unit; IgG: 
immunoglobulin G; IPA: invasive pulmonary aspergillosis; IQR: interquartile range; IRE: immunosuppression-
related event; MMF / MPA: mofetil mycophenolate / mycophenolate acid; mTOR: mammalian target of 
rapamycin; NA: not applicable; SD: standard deviation. 
a Significant P-values (<0.05) are expressed in bold. 
b Data available for 60 cases and 59 controls. 
c Data available for 59 cases and 54 controls. 
d Data available for 56 cases and 56 controls. 
e
 Data available for 54 cases and 54 controls. 
f At any point during the first 6 months after transplantation. 
g Data available for 59 cases and 59 controls. 
h
 Data available for 49 cases and 48 controls. 
i Serum IgG levels measured within the 6-month period prior to or following the date of diagnosis of IPA (for 
cases) or the analogous “pseudo-date” of diagnosis (for controls). Data available for 10 cases and 4 controls. 
j
 Events occurring within the 6-month period prior to the date or the “pseudo-date” of diagnosis of IPA. 
k
 The total number of IREs may be less than the sum of each conditions since more than one event was 
consecutively present in some patients. 
l There were 3 cases of post-transplant tuberculosis, although none of them occurred within the 6-month 
period prior to the date or the “pseudo-date” of diagnosis of IPA. 
m Includes PTLD (3 cases), colorectal adenocarcinoma and metastatic adenocarcinoma of unknown primary 
origin (one case each). 
n
 Includes influenza virus infection (4 cases). 
o Includes BSI due Enterobacteriaceae (3 cases), Pseudomonas aeruginosa, Staphylococcus epidermidis, S. 
aureus and Candida albicans (one case each). 
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Table 3. Uni- and multivariable analyses (conditional logistic regression) of risk factors 472 
predicting the occurrence of late IPA.  473 
Variables 
Univariate analysis  Multivariate analysis 
OR 95% CI P-value 
 
OR 95% CI P-value 
Age at transplantation, yearsa 1.04 1.01 - 1.08 0.017  - - - 
Diabetic nephropathy 3.00 0.97 - 9.30 0.057  - - - 
Pre-transplant COPD 65.29 0.51 - 8324.28 0.091  - - - 
Prior IREb,c 20.00 2.68 - 149.02 0.003  19.26 2.07 - 179.46 0.009 
Prior BSIb 7.00 0.86 - 56.89 0.069  - - - 
BSI: bloodstream infection; CI: confidence interval; COPD: chronic obstructive pulmonary disease; IPA: invasive pulmonary 
aspergillosis; IRE: immunosuppression-related event; OR: odds ratio. 
a OR per unitary increment. 
b Events occurring within the 6 months previous to the date of diagnosis of IPA for cases or the analogous “pseudo-date of 
diagnosis” for corresponding controls. 
c Includes non-ventilator-associated pneumonia, CMV disease and post-transplant de novo malignancy. 
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Figure legend 474 
• Figure 1. Temporal distribution of cases of late invasive pulmonary aspergillosis occurring 475 
according to post-transplant month of diagnosis. 476 
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Supporting Information 477 
Additional Supporting Information may be found in the online version of this article: 478 
• Supplementary Materials and Methods: Definitions used for date of IPA diagnosis, IPA-479 
attributable diagnosis, CMV disease, tuberculosis, pneumonia, respiratory tract viral 480 
infection, BSI, PTLD, delayed graft function, acute graft rejection and eGFR. 481 
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